Continued versus discontinued oxytocin stimulation in the active phase of labour (CONDISOX): double blind randomised controlled trial

Sidsel Boie, Julie Glavind, Niels Uldbjerg, Philip J Steer, Pinar Bor, CONDISOX trial group, Attila Bothazi, Iben Sundtoft, Jannet Bakker, Joris Van der Post, Kristina Martha Renault, Lene Drasbek Huusom, Lone Hvidman, Maja Thode Rask, Mohammed Khalil, Nini Møller, Tine Greve, Sidsel Boie, Julie Glavind, Niels Uldbjerg, Philip J Steer, Pinar Bor, CONDISOX trial group, Attila Bothazi, Iben Sundtoft, Jannet Bakker, Joris Van der Post, Kristina Martha Renault, Lene Drasbek Huusom, Lone Hvidman, Maja Thode Rask, Mohammed Khalil, Nini Møller, Tine Greve

Abstract

Objective: To determine whether discontinuing oxytocin stimulation in the active phase of induced labour is associated with lower caesarean section rates.

Design: International multicentre, double blind, randomised controlled trial.

Setting: Nine hospitals in Denmark and one in the Netherlands between 8 April 2016 and 30 June 2020.

Participants: 1200 women stimulated with intravenous oxytocin infusion during the latent phase of induced labour.

Intervention: Women were randomly assigned to have their oxytocin stimulation discontinued or continued in the active phase of labour.

Main outcome measure: Delivery by caesarean section.

Results: A total of 607 women were assigned to discontinuation and 593 to continuation of the oxytocin infusion. The rates of caesarean section were 16.6% (n=101) in the discontinued group and 14.2% (n=84) in the continued group (relative risk 1.17, 95% confidence interval 0.90 to 1.53). In 94 parous women with no previous caesarean section, the caesarean section rate was 7.5% (11/147) in the discontinued group and 0.6% (1/155)in the continued group (relative risk 11.6, 1.15 to 88.7). Discontinuation was associated with longer duration of labour (median from randomisation to delivery 282 v 201 min; P<0.001), a reduced risk of hyperstimulation (20/546 (3.7%) v 70/541 (12.9%); P<0.001), and a reduced risk of fetal heart rate abnormalities (153/548 (27.9%) v 219/537 (40.8%); P<0.001) but rates of other adverse maternal and neonatal outcomes were similar between groups.

Conclusions: In a setting where monitoring of the fetal condition and the uterine contractions can be guaranteed, routine discontinuation of oxytocin stimulation may lead to a small increase in caesarean section rate but a significantly reduced risk of uterine hyperstimulation and abnormal fetal heart rate patterns.

Trial registration: ClinicalTrials.gov NCT02553226.

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: support for the submitted work as detailed above; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Fig 1
Fig 1
Consort flow diagram
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8044921/bin/bois063027.va.jpg

References

    1. Martin JA, Hamilton BE, Osterman MJK, Driscoll AK. Births: Final Data for 2018. Natl Vital Stat Rep 2019;68:1-47.
    1. World Health Organization. WHO recommendations: Induction of labour at or beyond term. 2018. .
    1. Hedegaard M, Lidegaard Ø, Skovlund CW, Mørch LS, Hedegaard M. Reduction in stillbirths at term after new birth induction paradigm: results of a national intervention. BMJ Open 2014;4:e005785. 10.1136/bmjopen-2014-005785
    1. Daly D, Minnie KCS, Blignaut A, et al. . How much synthetic oxytocin is infused during labour? A review and analysis of regimens used in 12 countries. PLoS One 2020;15:e0227941. 10.1371/journal.pone.0227941
    1. Simpson KR, Knox GE. Oxytocin as a high-alert medication: implications for perinatal patient safety. MCN Am J Matern Child Nurs 2009;34:8-15, quiz 16-7. 10.1097/
    1. Oláh KS, Steer PJ. The use and abuse of oxytocin. Obstet Gynaecol 2015;17:265-71 10.1111/tog.12222.
    1. Mussi S, Incerti M, Plevani C, Ghidini A, Pezzullo JC, Locatelli A. Effect of oxytocin during labor on neonatal acidemia. J Matern Fetal Neonatal Med 2016;29:3098-103. 10.3109/14767058.2015.1114088
    1. Tribe RM, Crawshaw SE, Seed P, Shennan AH, Baker PN. Pulsatile versus continuous administration of oxytocin for induction and augmentation of labor: two randomized controlled trials. Am J Obstet Gynecol 2012;206:230.e1-8. 10.1016/j.ajog.2011.11.001
    1. Bostancı E, Kilicci C, Ozkaya E, Abide Yayla C, Eroglu M. Continuous oxytocin versus intermittent oxytocin for induction of labor: a randomized study. J Matern Fetal Neonatal Med 2020;33:651-6. 10.1080/14767058.2018.1499092
    1. Steer PJ, Carter MC, Choong K, Hanson M, Gordon AJ, Pradhan P. A multicentre prospective randomized controlled trial of induction of labour with an automatic closed-loop feedback controlled oxytocin infusion system. Br J Obstet Gynaecol 1985;92:1127-33. 10.1111/j.1471-0528.1985.tb03023.x
    1. Budden A, Chen LJY, Henry A. High-dose versus low-dose oxytocin infusion regimens for induction of labour at term. Cochrane Database Syst Rev 2014;(10):CD009701. 10.1002/14651858.CD009701.pub2
    1. Boie S, Glavind J, Velu AV, et al. . Discontinuation of intravenous oxytocin in the active phase of induced labour. Cochrane Database Syst Rev 2018;8:CD012274. 10.1002/14651858.CD012274.pub2
    1. Hernández-Martínez A, Arias-Arias A, Morandeira-Rivas A, Pascual-Pedreño AI, Ortiz-Molina EJ, Rodriguez-Almagro J. Oxytocin discontinuation after the active phase of induced labor: A systematic review. Women Birth 2019;32:112-8. 10.1016/j.wombi.2018.07.003
    1. Vlachos D-EG, Pergialiotis V, Papantoniou N, Trompoukis S, Vlachos GD. Oxytocin discontinuation after the active phase of labor is established. J Matern Fetal Neonatal Med 2015;28:1421-7. 10.3109/14767058.2014.955000
    1. Saccone G, Ciardulli A, Baxter JK, et al. . Discontinuing Oxytocin Infusion in the Active Phase of Labor: A Systematic Review and Meta-analysis. Obstet Gynecol 2017;130:1090-6. 10.1097/AOG.0000000000002325
    1. Eissaa AN, Sayyeda TM, El‐Halabya AE, Tahoonb RA. The outcome of induced labor after oxytocin infusion discontinuation in the active phase. Menoufia Med J 2019;32:441-7 10.4103/mmj.mmj_652_17.
    1. Mitra M, Sengupta M, Ghosal R, Saha C, Bandhya D, Ghosh D. Continuation versus Discontinuation of Oxytocin in Active Phase of Labour- A Randomised Trial. J Evol Med Dent Sci 2019;8:3342-6 10.14260/jemds/2019/725.
    1. Boie S, Glavind J, Uldbjerg N, et al. . CONDISOX- continued versus discontinued oxytocin stimulation of induced labour in a double-blind randomised controlled trial. BMC Pregnancy Childbirth 2019;19:320. 10.1186/s12884-019-2461-x
    1. Marsál K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr 1996;85:843-8. 10.1111/j.1651-2227.1996.tb14164.x
    1. Magann EF, Doherty DA, Chauhan SP, Busch FWJ, Mecacci F, Morrison JC. How well do the amniotic fluid index and single deepest pocket indices (below the 3rd and 5th and above the 95th and 97th percentiles) predict oligohydramnios and hydramnios? Am J Obstet Gynecol 2004;190:164-9. 10.1016/S0002-9378(03)00859-7
    1. Harris PA, Taylor R, Minor BL, et al. REDCap Consortium . The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019;95:103208. 10.1016/j.jbi.2019.103208
    1. Boie S, Lauridsen HH, Glavind J, Smed MK, Uldbjerg N, Bor P. The Childbirth Experience Questionnaire (CEQ)-Validation of its use in a Danish-speaking population of new mothers stimulated with oxytocin during labour. PLoS One 2020;15:e0233122. 10.1371/journal.pone.0233122
    1. Bor P, Ledertoug S, Boie S, Knoblauch NO, Stornes I. Continuation versus discontinuation of oxytocin infusion during the active phase of labour: a randomised controlled trial. BJOG 2016;123:129-35. 10.1111/1471-0528.13589
    1. Fayers PM, Machin D. Quality of Life: The Assessment, Analysis, and Interpretation of Patient-Reported Outcomes. 2nd ed. John Wiley & Sons, 2013.
    1. Rooth G, Huch A, Huch R. Guidelines for the use of Fetal Monitoring. Int J Gynecol Obstet 1987;25:159-67.
    1. Diven LC, Rochon ML, Gogle J, Eid S, Smulian JC, Quiñones JN. Oxytocin discontinuation during active labor in women who undergo labor induction. Am J Obstet Gynecol 2012;207:471.e1-8. 10.1016/j.ajog.2012.08.035
    1. Ekelin M, Svensson J, Evehammar S, Kvist LJ. Sense and sensibility: Swedish midwives’ ambiguity to the use of synthetic oxytocin for labour augmentation. Midwifery 2015;31:e36-42. 10.1016/j.midw.2014.12.006
    1. World Health Organization . WHO recommendations for induction of labour. WHO, 2011.
    1. Dencker A, Berg M, Bergqvist L, Ladfors L, Thorsén LS, Lilja H. Early versus delayed oxytocin augmentation in nulliparous women with prolonged labour--a randomised controlled trial. BJOG 2009;116:530-6. 10.1111/j.1471-0528.2008.01962.x

Source: PubMed

3
订阅